Alternative influenza vaccines made by insect cells

Trends in Molecular Medicine

Volumn 16, Issue 7, 2010, Pages 313-320

  Krammer, Florian ^a   Grabherr, Reingard ^a  

^a UNIVERSITY OF NATURAL RESOURCES AND LIFE SCIENCES   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

HEMAGGLUTININ; INFLUENZA VACCINE; RECOMBINANT ENZYME; RECOMBINANT PROTEIN; SIALIDASE;

BACULOVIRUS; GLYCOSYLATION; HUMAN; INSECT CELL; MORBIDITY; MORTALITY; NONHUMAN; REVIEW; VIRUS LIKE AGENT; VIRUS PARTICLE;

ANIMALS; BACULOVIRIDAE; INFLUENZA VACCINES; INSECTS; TRANSDUCTION, GENETIC; VIRAL PROTEINS; VIRION;

HEXAPODA; ORTHOMYXOVIRIDAE; SUIDAE;

EID: 77954385193     PISSN: 14714914     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molmed.2010.05.002     Document Type: Review

References (74)

1. Smith G., et al. Origins and evolutionary genomics of the 2009 swine-origin H1N1 influenza A epidemic. Nature 2009, 459:1122-1125.
2. Peiris J., et al. A novel H1N1 virus causes the first pandemic of the 21(st) century. Eur. J. Immunol. 2009, 39:2946-2954.
3. Ryan J., et al. Establishing the health and economic impact of influenza vaccination within the European Union 25 countries. Vaccine 2006, 24:6812-6822.
4. Smith W., et al. A virus obtained from influenza patients. The Lancet 1933, 66-68.
5. Gerdil C. The annual production cycle for influenza vaccine. Vaccine 2003, 21:1776-1779.
6. Tree J., et al. Comparison of large-scale mammalian cell culture systems with egg culture for the production of influenza virus A vaccine strains. Vaccine 2001, 19:3444-3450.
7. Robertson J., et al. Structural changes in the haemagglutinin which accompany egg adaptation of an influenza A(H1N1) virus. Virology 1987, 160:31-37.
8. Erlewyn-Lajeunesse M., et al. Recommendations for the administration of influenza vaccine in children allergic to egg. BMJ 2009, 339:b3680.
9. Kistner O., et al. Cell culture (Vero) derived whole virus (H5N1) vaccine based on wild-type virus strain induces cross-protective immune responses. Vaccine 2007, 25:6028-6036.
10. Kistner O., et al. Development of a mammalian cell (Vero) derived candidate influenza virus vaccine. Vaccine 1998, 16:960-968.
11. Romanova J., et al. Preclinical evaluation of a replication-deficient intranasal DeltaNS1 H5N1 influenza vaccine. PLoS One 2009, 4:e5984.
12. Huleatt J., et al. Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin. Vaccine 2008, 26:201-214.
13. D'Aoust M., et al. The production of hemagglutinin-based virus-like particles in plants: a rapid, efficient and safe response to pandemic influenza. Plant Biotechnol. J. 2010.
14. Richardson C.D. Baculovirus Expression Protocols 1995, Humana Press.
15. Hu Y. Baculoviral vectors for gene delivery: a review. Curr. Gene. Ther. 2008, 8:54-65.
16. Boyce F., Bucher N. Baculovirus-mediated gene transfer into mammalian cells. Proc. Natl. Acad. Sci. U. S. A. 1996, 93:2348-2352.
17. Abe T., et al. Involvement of the Toll-like receptor 9 signaling pathway in the induction of innate immunity by baculovirus. J. Virol. 2005, 79:2847-2858.
18. Kost T., Condreay J. Recombinant baculoviruses as mammalian cell gene-delivery vectors. Trends Biotechnol. 2002, 20:173-180.
19. Spenger A., et al. Influence of promoter choice and trichostatin A treatment on expression of baculovirus delivered genes in mammalian cells. Protein Expr. Purif. 2004, 38:17-23.
20. Inceoglu A., et al. Recombinant baculoviruses for insect control. Pest Manag. Sci. 2001, 57:981-987.
21. Cox M. Progress on baculovirus-derived influenza vaccines. Curr. Opin. Mol. Ther. 2008, 10:56-61.
22. Kost T., et al. Baculovirus as versatile vectors for protein expression in insect and mammalian cells. Nat. Biotechnol. 2005, 23:567-575.
23. Vaughn J., et al. The establishment of two cell lines from the insect Spodoptera frugiperda (Lepidoptera; Noctuidae). In Vitro 1977, 13:213-217.
24. Hink W. Established insect cell line from the cabbage looper, Trichoplusia ni. Nature 1970, 226:466-467.
25. Rhiel M., et al. Comparison of Trichoplusia ni BTI-Tn-5B1-4 (high five) and Spodoptera frugiperda Sf-9 insect cell line metabolism in suspension cultures. Biotechnol. Bioeng. 1997, 55:909-920.
26. Hink, W. et al. Expression of three recombinant proteins using baculovirus vectors in 23 insect cell lines. Biotechnol. Prog. 7, 9-14.
27. Wickham, T. et al. Screening of insect cell lines for the production of recombinant proteins and infectious virus in the baculovirus expression system. Biotechnol. Prog. 8, 391-396.
28. Saarinen M., et al. Recombinant protein synthesis in Trichoplusia ni BTI-Tn-5B1-4 insect cell aggregates. Biotechnol. Bioeng. 1999, 63:612-617.
29. Kost T., Condreay J. Recombinant baculoviruses as expression vectors for insect and mammalian cells. Curr. Opin. Biotechnol. 1999, 10:428-433.
30. Ikonomou L., et al. Insect cell culture for industrial production of recombinant proteins. Appl. Microbiol. Biotechnol. 2003, 62:1-20.
31. Bernal V., et al. Cell density effect in the baculovirus-insect cells system: a quantitative analysis of energetic metabolism. Biotechnol. Bioeng. 2009, 104:162-180.
32. Cruz P., et al. Optimization of the production of virus-like particles in insect cells. Biotechnol. Bioeng. 1998, 60:408-418.
33. Meghrous J., et al. Development of a simple and high-yielding fed-batch process for the production of influenza vaccines. Vaccine 2009, 28:309-316.
34. Rendic, D. et al. (2008) The Glycosylation Capacity of Insect Cells. pp. 7-21.
35. Aoki K., et al. Dynamic developmental elaboration of N-linked glycan complexity in the Drosophila melanogaster embryo. J. Biol. Chem. 2007, 282:9127-9142.
36. Hancock K., et al. False positive reactivity of recombinant, diagnostic, glycoproteins produced in High Five insect cells: effect of glycosylation. J. Immunol. Methods 2008, 330:130-136.
37. Altmann F., et al. Insect cells as hosts for the expression of recombinant glycoproteins. Glycoconj J. 1999, 16:109-123.
38. Rendić D., et al. Adaptation of the " in-gel release method" to N-glycome analysis of low-milligram amounts of material. Electrophoresis 2007, 28:4484-4492.
39. Schiller J., et al. An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results. Vaccine 2008, 26(Suppl 10):K53-61.
40. Cox M., et al. FluBlok, a recombinant hemagglutinin influenza vaccine. Influenza Other Respi. Viruses 2008, 2:211-219.
41. Treanor J. Recombinant proteins produced in insect cells. Curr. Top. Microbiol. Immunol. 2009, 333:211-225.
42. Powers D., et al. Humoral and cellular immune responses following vaccination with purified recombinant hemagglutinin from influenza A (H3N2) virus. J. Infect. Dis. 1997, 175:342-351.
43. Dalakouras T., et al. Development of recombinant protein-based influenza vaccine. Expression and affinity purification of H1N1 influenza virus neuraminidase. J. Chromatogr. A 2006, 1136:48-56.
44. Krammer, F. et al. (2010) Trichoplusia ni cells (High Five™) are highly efficient for the production of influenza A virus-like particles: a comparison of two insect cell lines as production platforms for influenza vaccines. Mol. Biotechnol. doi:10.1007/s12033-010-9268-3.
45. Quan F., et al. Virus-like particle vaccine induces protective immunity against homologous and heterologous strains of influenza virus. J. Virol. 2007, 81:3514-3524.
46. Latham T., Galarza J. Formation of wild-type and chimeric influenza virus-like particles following simultaneous expression of only four structural proteins. J. Virol. 2001, 75:6154-6165.
47. Pushko P., et al. Influenza virus-like particles comprised of the HA, NA, and M1 proteins of H9N2 influenza virus induce protective immune responses in BALB/c mice. Vaccine 2005, 23:5751-5759.
48. Quan F., et al. A bivalent influenza VLP vaccine confers complete inhibition of virus replication in lungs. Vaccine 2008, 26:3352-3361.
49. Galarza J., et al. Virus-like particle (VLP) vaccine conferred complete protection against a lethal influenza virus challenge. Viral Immunol. 2005, 18:244-251.
50. Bright R., et al. Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin. Vaccine 2007, 25:3871-3878.
51. Mahmood K., et al. H5N1 VLP vaccine induced protection in ferrets against lethal challenge with highly pathogenic H5N1 influenza viruses. Vaccine 2008, 26:5393-5399.
52. Crevar C., Ross T. Elicitation of protective immune responses using a bivalent H5N1 VLP vaccine. Virol. J. 2008, 5:131.
53. Tao P., et al. Virus-like particle vaccine comprised of the HA, NA, and M1 proteins of an avian isolated H5N1 influenza virus induces protective immunity against homologous and heterologous strains in mice. Viral Immunol. 2009, 22:273-281.
54. Kang S., et al. Induction of long-term protective immune responses by influenza H5N1 virus-like particles. PLoS One 2009, 4:e4667.
55. Ross T., et al. A trivalent virus-like particle vaccine elicits protective immune responses against seasonal influenza strains in mice and ferrets. PLoS One 2009, 4:e6032.
56. Quan F., et al. Kinetics of immune responses to influenza virus-like particles and dose-dependence of protection with a single vaccination. J. Virol. 2009, 83:4489-4497.
57. Quan F., et al. Virus-like particle vaccine protects against 2009 H1N1 pandemic influenza virus in mice. PLoS One 2010, 5:e9161.
58. Haynes J., et al. Influenza-pseudotyped Gag virus-like particle vaccines provide broad protection against highly pathogenic avian influenza challenge. Vaccine 2009, 27:530-541.
59. Wang B., et al. Incorporation of membrane-anchored flagellin into influenza virus-like particles enhances the breadth of immune responses. J. Virol. 2008, 82:11813-11823.
60. Krammer, F. et al. (2010) Influenza virus-like particles as an antigen-carrier platform for the ESAT-6 epitope of Mycobacterium tuberculosis. J Virol Methods doi:10.1016/j.jviromet.2010.03.003.
61. Abe T., et al. Baculovirus induces an innate immune response and confers protection from lethal influenza virus infection in mice. J. Immunol. 2003, 171:1133-1139.
62. Krammer F., et al. Swine-origin pandemic H1N1 influenza virus-like particles produced in insect cells induce hemagglutination inhibiting antibodies in BALB/c mice. Biotechnol. J. 2010, 5:17-23.
63. Nakowitsch S., et al. Optimization of baculovirus transduction on FreeStyle293 cells for the generation of influenza B/Lee/40. Mol. Biotechnol. 2006, 34:157-164.
64. Ernst W., et al. Improving baculovirus transduction of mammalian cells by surface display of a RGD-motif. J. Biotechnol. 2006, 126:237-240.
65. Prabakaran M., et al. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant. Virology 2008, 380:412-420.
66. Prabakaran M., et al. Gastrointestinal delivery of baculovirus displaying influenza virus hemagglutinin protects mice against heterologous H5N1 infection. J. Virol. 2010, 84:3201-3209.
67. Wu Q., et al. A pseudotype baculovirus-mediated vaccine confers protective immunity against lethal challenge with H5N1 avian influenza virus in mice and chickens. Mol. Immunol. 2009, 46:2210-2217.
68. Prabakaran M., et al. Reverse micelle-encapsulated recombinant baculovirus as an oral vaccine against H5N1 infection in mice. Antiviral Res. 2010, 86:180-187.
69. Merrihew R., et al. Chromosomal integration of transduced recombinant baculovirus DNA in mammalian cells. J. Virol. 2001, 75:903-909.
70. Ruedl C., et al. Cross-presentation of virus-like particles by skin-derived CD8(-) dendritic cells: a dispensable role for TAP. Eur. J. Immunol. 2002, 32:818-825.
71. Ruedl C., et al. Virus-like particles as carriers for T-cell epitopes: limited inhibition of T-cell priming by carrier-specific antibodies. J. Virol. 2005, 79:717-724.
72. Schäfer K., et al. Immune response to human papillomavirus 16 L1E7 chimeric virus-like particles: induction of cytotoxic T cells and specific tumor protection. Int. J. Cancer 1999, 81:881-888.
73. Sedlik C., et al. Recombinant parvovirus-like particles as an antigen carrier: a novel nonreplicative exogenous antigen to elicit protective antiviral cytotoxic T cells. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:7503-7508.
74. Perrone L., et al. Intranasal vaccination with 1918 influenza virus-like particles protects mice and ferrets from lethal 1918 and H5N1 influenza virus challenge. J. Virol. 2009, 83:5726-5734.